On Friday, Piper Sandler increased its price target for Integer Holdings (NYSE:NYSE:ITGR) shares to $140 from $125, while maintaining an Overweight rating on the stock.
The adjustment follows the release of Integer's third-quarter results, which met expectations in terms of revenue when accounting for divestitures and exceeded forecasts on the bottom line. The company has kept its revenue guidance steady but has raised its operating profit growth outlook by 100 basis points.
Integer's Cardio & Vascular (C&V) business, which is the largest part of the company and a key growth driver, delivered results that fell slightly short of expectations. This performance has put some pressure on the company's shares today.
Piper Sandler noted that results from contract manufacturers like Integer can exhibit volatility, which was evident in the C&V business this quarter. The firm anticipates an uplift in the latter half of the year, driven by improved growth in percutaneous coronary intervention (PCI), mitral, and tricuspid valve treatments, among others.
Piper Sandler's analyst believes that the current dip in Integer's stock price, described as a high single-digit percentage (HSD) pullback, presents an opportunity for investors to initiate or increase their holdings in Integer. The firm's recommendation to investors is to leverage the temporary decline in share value to invest in a company they rate as Overweight.
Integer Holdings is a medical device outsource manufacturer that provides comprehensive solutions for medical device OEMs. The company specializes in producing components and assemblies that are integral to the creation of medical devices and technologies used in cardiovascular and other critical care applications.
The updated price target reflects Piper Sandler's confidence in Integer's potential for growth and profitability, despite the short-term challenges faced by the C&V business segment. The firm's Overweight rating indicates a bullish outlook on the stock, suggesting that Integer Holdings may outperform the broader market or its sector in the foreseeable future.
In other recent news, Integer Holdings reported robust third-quarter results, with earnings per share (EPS) exceeding expectations at $1.43, outperforming both CL King's projection of $1.39 and the consensus estimate of $1.36.
However, the company's revenue of $431.4 million fell short of anticipated figures, partly due to the reclassification of the Electrochem business. Organic growth for the quarter was reported at 4.3%, with varying performances across its segments.
Recent developments include the company's updated full-year 2024 forecast, now expecting revenues to range between $1,707 million and $1,727 million, indicating an increase of 10% to 11%. This is a slight uptick from the previous forecast of 9% to 11% growth. The revised outlook includes an anticipated 7% to 8% organic growth.
Despite a slight deceleration in organic growth to 4% for Q3 due to lower-than-expected CRM demand and minor disruptions from Hurricane Helene, Integer remains confident in its growth strategy. The company anticipates a combined sales growth of 29% and a 56% increase in adjusted operating income over 2023 and 2024.
CL King reiterated a Buy rating for Integer's stock and set a price target of $137.00, despite the mixed third-quarter results. For the fourth quarter of 2024, Integer anticipates sequential sales growth driven by new product launches and increased guidewire capacity. The adjusted EPS forecast has been raised to $5.24 to $5.43.
Integer Holdings has also reported key leadership changes and the divestiture of the Electrochem business. The company's adjusted EBITDA is forecasted between $358 million and $368 million, an 18% to 21% year-over-year rise. Integer expects accelerated organic growth in Q4, especially in the Cardio & Vascular and Neuromodulation segments.
InvestingPro Insights
Integer Holdings (NYSE:ITGR) has shown strong financial performance, aligning with Piper Sandler's optimistic outlook. According to InvestingPro data, the company's revenue grew by 10.07% over the last twelve months, with a notable 21.44% increase in EBITDA during the same period. This growth trajectory supports the analyst's positive stance on the stock.
InvestingPro Tips highlight that Integer is trading near its 52-week high and has delivered a high return over the last year, with a remarkable 82.6% price total return. This performance underscores the company's strong market position and potential for continued growth, as suggested by Piper Sandler's increased price target.
However, investors should note that Integer is trading at a high earnings multiple, with a P/E ratio of 38.02. This valuation metric indicates that the market has high expectations for future growth, which aligns with the company's raised operating profit growth outlook mentioned in the article.
For those considering Integer as an investment opportunity, InvestingPro offers 7 additional tips to further inform your decision-making process. These insights can provide a more comprehensive view of Integer's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.